Results 61 to 70 of about 10,615 (182)

OX1 and OX2 orexin/hypocretin receptor pharmacogenetics [PDF]

open access: yesFrontiers in Neuroscience, 2014
Orexin/hypocretin peptide mutations are rare in humans. Even though human narcolepsy is associated with orexin deficiency, this is only extremely rarely due to mutations in the gene coding prepro-orexin, the precursor for both orexin peptides. In contrast, coding and non-coding variants of the OX1 and OX2 orexin receptors have been identified in many ...
Miles Douglas Thompson   +5 more
openaire   +4 more sources

Use of Dual Orexin Receptor Antagonists for Insomnia and the Risk of Falls and Fractures: A Systematic Review and Meta‐Analysis

open access: yesJournal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Falls are the leading cause of injury in older adults. Sedative‐hypnotic use is a known risk factor, but their use for insomnia continues to be common. Dual orexin receptor antagonists (DORAs) are a new, potentially safer class of medications for insomnia.
Arianna Paolone   +5 more
wiley   +1 more source

Hip Fracture Risk of Lemborexant and Suvorexant in Comparison With Z‐Drugs: A Target Trial Emulation

open access: yesJournal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Lemborexant and suvorexant are widely used dual orexin receptor antagonists (DORAs) for the pharmacological treatment of insomnia. Although they are generally considered safer than benzodiazepine receptor agonists (Z‐drugs) regarding adverse events including hip fractures, evidence from direct comparisons remains limited. This study
Yuichiro Matsuo   +5 more
wiley   +1 more source

Chronic insomnia, REM sleep instability and emotional dysregulation: A pathway to anxiety and depression?

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary The world‐wide prevalence of insomnia disorder reaches up to 10% of the adult population. Women are more often afflicted than men, and insomnia disorder is a risk factor for somatic and mental illness, especially depression and anxiety disorders.
Dieter Riemann   +13 more
wiley   +1 more source

SB‐334867‐A: the first selective orexin‐1 receptor antagonist [PDF]

open access: yesBritish Journal of Pharmacology, 2001
The pharmacology of various peptide and non‐peptide ligands was studied in Chinese hamster ovary (CHO) cells stably expressing human orexin‐1 (OX1) or orexin‐2 (OX2) receptors by measuring intracellular calcium ([Ca2+]i) using Fluo‐3AM. Orexin‐A and orexin‐B increased [Ca2+]i in CHO‐OX1 (pEC50=8.38±0.04 and 7.26±0.05 respectively, n=12) and CHO‐OX2 ...
D, Smart   +6 more
openaire   +2 more sources

Narcolepsy and rapid eye movement sleep

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Since the first description of narcolepsy at the end of the 19th Century, great progress has been made. The disease is nowadays distinguished as narcolepsy type 1 and type 2. In the 1960s, the discovery of rapid eye movement sleep at sleep onset led to improved understanding of core sleep‐related disease symptoms of the disease (excessive ...
Francesco Biscarini   +4 more
wiley   +1 more source

Role of orexin receptors in histamine- and chloroquine-induced pruriceptive processing

open access: yesNeuroscience Research
It is known that orexin peptides are involved in nociceptive processing, while little is known about the roles of these peptides in itch processing. To reveal the functions of orexin peptides in pruriceptive processing, orexin A (OX-A) and orexin B (OX-B)
Anna Kanemaru-Kawazoe   +7 more
doaj   +1 more source

Ageing‐related modification of sleep and breathing in orexin‐knockout narcoleptic mice

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Narcolepsy type‐1 (NT1) is a lifelong sleep disease, characterised by impairment of the orexinergic system, with a typical onset during adolescence and young adulthood. Since the wake–sleep cycle physiologically changes with ageing, this study aims to compare sleep patterns between orexin‐knockout (KO) and wild type (WT) control mice at ...
Stefano Bastianini   +7 more
wiley   +1 more source

On the kinetic features of orexin receptor antagonists at orexin receptors, transduction systems and receptor binding

open access: yesMedicine in Drug Discovery
Orexin receptor antagonists are on the market or under development for the treatment of insomnia and a number of other neuropsychiatric disorders. Currently, suvorexant, lemborexant and daridorexant, three dual orexin receptor antagonists (DORAs) have ...
Daniel Hoyer, Laura H. Jacobson
doaj   +1 more source

Orexin receptor antagonists reverse aberrant dopamine neuron activity and related behaviors in a rodent model of stress-induced psychosis

open access: yesTranslational Psychiatry, 2021
Post-traumatic stress disorder (PTSD) is a prevalent condition affecting approximately 8% of the United States population and 20% of United States combat veterans. In addition to core symptoms of the disorder, up to 64% of individuals diagnosed with PTSD
Hannah B. Reiley   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy